Japan’s AGC Makes Agreed €240m Bid For MolMed

Silvio Berlusconi’s Fininvest holds 23% in the cancer-focused biotech

17 Mar 2020

• By Sten Stovall

AGC of Japan is offering to buy cell and gene therapy specialist MolMed SPA in a deal worth up to €240m and backed by the biotech’s biggest shareholder, Silvio Berlusconi’s Fininvest.

M&A — AGC wants to catch clinical-stage Italian biotech MolMed • Source: Shutterstock

AGC Inc. of Japan, part of the Mitsubishi conglomerate, has launched a takeover bid for all of Milan-based MolMed SPA in a deal valued at €240m and which is being backed by the biotech’s biggest shareholder, former Italian Prime Minister Silvio Berlusconi’s investment vehicle Fininvest.

Tokyo-based AGC, formerly known as Asahi Glass Co., said in a brief statement on 17 March that it was offering €0

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

09 May 2025

• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

09 May 2025

• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Building Up US Biopharma Manufacturing Will Require Investments In Talent

09 May 2025

• By Jessica Merrill

Workforce development will be essential to meeting president Trump’s goal to return biopharma manufacturing to the US.

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.